Clinical Trials

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

75 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT07492641 2026-05-22

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07340541 2026-05-20

EVOLVE-BDT

700 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06760637 2026-05-19

FourLight-3

1,035 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07100106 2026-05-18

MoonROSE

285 enrolled

Breast Neoplasms

NCT02693535 2026-05-15

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT05372640 2026-05-13

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

74 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06654037 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Phase 1 Recruiting

39 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04010357 2026-05-12

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Phase 2 Completed

14 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06188520 2026-05-11

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT02523014 2026-05-08

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

124 enrolled

CNS

Meningioma

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04941274 2026-05-05

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

111 enrolled

Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT05872204 2026-05-05

ALEPRO

100 enrolled

Gynecologic

Low Grade Serous Ovarian Carcinoma

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT04305834 2026-05-04

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Breast Neoplasms

NCT06835972 2026-05-04

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)